|
FR3046933B1
(fr)
*
|
2016-01-25 |
2018-03-02 |
Galderma Research & Development |
Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
|
|
US11339136B2
(en)
|
2016-04-18 |
2022-05-24 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
EP3571187B1
(en)
|
2017-01-23 |
2023-11-22 |
Genentech, Inc. |
Chemical compounds as inhibitors of interleukin-1 activity
|
|
JP7072586B2
(ja)
|
2017-05-24 |
2022-05-20 |
ザ ユニバーシティ オブ クィーンズランド |
新規な化合物及び使用
|
|
NZ760129A
(en)
|
2017-07-07 |
2025-12-19 |
Inflazome Ltd |
Novel sulfonamide carboxamide compounds
|
|
EP3649112A1
(en)
|
2017-07-07 |
2020-05-13 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
|
|
ES2988798T3
(es)
|
2017-07-24 |
2024-11-21 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
|
|
JP7349981B2
(ja)
*
|
2017-07-24 |
2023-09-25 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
|
|
UY37848A
(es)
*
|
2017-08-15 |
2019-03-29 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
|
|
EP3668843A1
(en)
|
2017-08-15 |
2020-06-24 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
|
|
MA49903A
(fr)
|
2017-08-15 |
2020-06-24 |
Inflazome Ltd |
Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
WO2019092171A1
(en)
|
2017-11-09 |
2019-05-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
CN111315733A
(zh)
*
|
2017-11-09 |
2020-06-19 |
英夫拉索姆有限公司 |
新颖磺酰胺甲酰胺化合物
|
|
US11905252B2
(en)
|
2018-03-02 |
2024-02-20 |
Inflazome Limited |
Compounds
|
|
EP3759073A1
(en)
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Sulfonamide derivates as nlrp3 inhibitors
|
|
GB201803394D0
(en)
*
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
GB201803393D0
(en)
*
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166627A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
MX2020011501A
(es)
|
2018-05-04 |
2020-12-07 |
Inflazome Ltd |
Compuestos novedosos.
|
|
JP2021529186A
(ja)
*
|
2018-07-03 |
2021-10-28 |
ノバルティス アーゲー |
Ｎｌｒｐ調節剤
|
|
AU2019299444A1
(en)
|
2018-07-03 |
2021-01-14 |
Novartis Ag |
Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist
|
|
EP3817817A1
(en)
*
|
2018-07-03 |
2021-05-12 |
Novartis AG |
Nlrp modulators
|
|
CR20210024A
(es)
|
2018-07-20 |
2021-02-22 |
Hoffmann La Roche |
Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
|
|
CA3105521A1
(en)
|
2018-07-20 |
2020-01-23 |
F. Hoffmann-La Roche Ag |
Sulfonimidamide compounds as inhibitors of interleukin-1 activity
|
|
KR20210053910A
(ko)
|
2018-08-15 |
2021-05-12 |
인플라좀 리미티드 |
신규한 설폰아마이드유레아 화합물
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
JP2022505525A
(ja)
*
|
2018-10-24 |
2022-01-14 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
|
|
ES3042546T3
(en)
*
|
2018-11-13 |
2025-11-21 |
Novartis Ag |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
EP3880673B1
(en)
*
|
2018-11-13 |
2024-01-03 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
US12134611B2
(en)
|
2018-11-13 |
2024-11-05 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
WO2020102574A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Novartis Inflammasome Research, Inc. |
The compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201819083D0
(en)
*
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
EA202191968A1
(ru)
|
2019-01-14 |
2021-11-16 |
Кадила Хелзкэр Лимитед |
Новые замещенные производные сульфонилмочевины
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
CN111848461A
(zh)
*
|
2019-04-29 |
2020-10-30 |
苏州大学 |
Nlrp3炎症小体抑制剂及其制备方法和应用
|
|
EP3983070B1
(en)
*
|
2019-06-17 |
2024-09-11 |
Olatec Therapeutics, Inc. |
Method for treating asthma
|
|
EP3986879B1
(en)
|
2019-06-21 |
2024-10-02 |
AC Immune SA |
Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators
|
|
WO2021002887A1
(en)
*
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
|
EP3999179A1
(en)
|
2019-07-17 |
2022-05-25 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
KR20220064364A
(ko)
*
|
2019-07-17 |
2022-05-18 |
조마젠 바이오사이언시즈 엘티디 |
다발성 경화증(ms)의 치료를 위한 nlpr3 조절제로서의 n-((1,2,3,5,6,7-헥사하이드로-s-인다센-4-일)카바모일)-4,5,6,7-테트라하이드로벤조푸란-2-설폰아미드 유도체 및 관련 화합물
|
|
JP2022545400A
(ja)
|
2019-08-16 |
2022-10-27 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤として有用な大環状スルホニル尿素誘導体
|
|
US20220289692A1
(en)
|
2019-09-06 |
2022-09-15 |
Inflazome Limited |
Nlrp3 inhibitors
|
|
CN111100042B
(zh)
*
|
2019-11-18 |
2022-05-31 |
苏州诚和医药化学有限公司 |
一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
|
|
CN111018750B
(zh)
*
|
2019-12-19 |
2022-05-27 |
苏州诚和医药化学有限公司 |
一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
WO2021165245A1
(en)
|
2020-02-18 |
2021-08-26 |
Inflazome Limited |
Compounds
|
|
PH12022552447A1
(en)
*
|
2020-03-16 |
2024-01-03 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
CN115297855A
(zh)
|
2020-03-19 |
2022-11-04 |
索芙特海尔公司 |
治疗nlrp3相关的疾病的方法
|
|
US12428391B2
(en)
|
2020-06-11 |
2025-09-30 |
Cisen Pharmaceutical Co., Ltd |
Dimethylsulfoximine derivative
|
|
AU2021291065B2
(en)
|
2020-06-19 |
2025-06-26 |
Ac Immune Sa |
Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
CN117279903A
(zh)
*
|
2021-02-10 |
2023-12-22 |
杭州英创医药科技有限公司 |
作为nlrp3抑制剂的化合物
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
CN116635374B
(zh)
*
|
2021-05-10 |
2025-05-06 |
康百达（四川）生物医药科技有限公司 |
酰胺衍生物及其应用
|
|
WO2023098612A1
(zh)
*
|
2021-12-03 |
2023-06-08 |
南京明德新药研发有限公司 |
二甲基亚磺酰亚胺衍生物的盐型及晶型
|
|
CN118541366A
(zh)
|
2021-12-22 |
2024-08-23 |
Ac免疫有限公司 |
二氢噁唑衍生物化合物
|
|
EP4554945A1
(en)
|
2022-07-14 |
2025-05-21 |
AC Immune SA |
Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
|
|
AU2023313032A1
(en)
|
2022-07-28 |
2025-01-23 |
Ac Immune Sa |
Novel compounds
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
AU2024280075A1
(en)
|
2023-06-02 |
2025-12-11 |
Merck Sharp & Dohme Llc |
5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
WO2025153532A1
(en)
|
2024-01-16 |
2025-07-24 |
NodThera Limited |
Nlrp3 inhibitors and glp-1 agonists combination therapies
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
WO2026057747A1
(en)
|
2024-09-11 |
2026-03-19 |
Ac Immune Sa |
Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
|